Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Cytek Biosciences Inc (NQ: CTKB )

5.490 +0.080 (+1.48%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 16, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 549,188
Open 5.370
Bid (Size) 5.480 (54)
Ask (Size) 5.490 (18)
Prev. Close 5.410
Today's Range 5.330 - 5.545
52wk Range 3.800 - 9.870
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
CTKB Stock Earnings: Cytek Biosciences Misses EPS, Misses Revenue for Q2 2024
CTKB stock results show that Cytek Biosciences missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
Via InvestorPlace
Cytek® Biosciences Automates Panel Design with New Intelligent Algorithm
Expanding Capabilities and Streamlining Experimental Workflows 
From Cytek Biosciences, Inc.
Via GlobeNewswire

Performance

YTD
-38.11%
-38.11%
1 Month
-17.57%
-17.57%
3 Month
-11.17%
-11.17%
6 Month
-37.04%
-37.04%
1 Year
-34.29%
-34.29%

More News

Read More
Cytek Biosciences Announces $50 Million Stock Repurchase Program
From Cytek Biosciences, Inc.
Via GlobeNewswire
The Latest Analyst Ratings for Cytek Biosciences
Via Benzinga
Cytek Biosciences to participate at the Goldman Sachs 45th Annual Global Healthcare Conference
From Cytek Biosciences, Inc.
Via GlobeNewswire
1-Laser and 2-Laser 6-Color TBNK Reagents from Cytek® Biosciences Approved for Clinical Use in China
From Cytek Biosciences, Inc.
Via GlobeNewswire
Cytek® Biosciences Adds Ability to Detect Subcellular Particles to Its Industry-Leading Cell Analysis Systems
From Cytek Biosciences, Inc.
Via GlobeNewswire
CTKB Stock Earnings: Cytek Biosciences Misses EPS, Beats Revenue for Q1 2024
Via InvestorPlace
Cytek Biosciences Reports First Quarter 2024 Financial Results
From Cytek Biosciences, Inc.
Via GlobeNewswire
Cytek® Biosciences to Spotlight Cell Analysis Solutions at Upcoming Conferences in the United States and Europe
From Cytek Biosciences, Inc.
Via GlobeNewswire
Cytek Biosciences to Report First Quarter 2024 Financial Results on May 8, 2024
From Cytek Biosciences, Inc.
Via GlobeNewswire
CTKB Stock Earnings: Cytek Biosciences Beats Revenue for Q4 2023
Via InvestorPlace
Cytek® Biosciences Names William McCombe Chief Financial Officer
From Cytek Biosciences, Inc.
Via GlobeNewswire
Cytek® Biosciences Opens New Facility to Address Increasing Global Demand for Cutting-Edge Cell Analysis Solutions
From Cytek Biosciences, Inc.
Via GlobeNewswire
Tesla, Spirit Airlines, New York Community Bancorp And Other Big Stocks Moving Lower On Monday
Via Benzinga
Topics Stocks
Exposures US Equities
Why Butterfly Network Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Cytek Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Outlook
From Cytek Biosciences, Inc.
Via GlobeNewswire
Cytek Biosciences to Participate in Upcoming Investor Conferences
From Cytek Biosciences, Inc.
Via GlobeNewswire
Cytek Biosciences to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024
From Cytek Biosciences, Inc.
Via GlobeNewswire
Cytek® Biosciences Signs Agreement with CRG and UPF to Accelerate Scientific Discoveries
From Cytek Biosciences, Inc.
Via GlobeNewswire
Cytek Biosciences Announces Preliminary Full Year 2023 Revenue Results
From Cytek Biosciences, Inc.
Via GlobeNewswire
Cytek Biosciences to present at the 42nd Annual J.P. Morgan Healthcare Conference
From Cytek Biosciences, Inc.
Via GlobeNewswire
Cytek® Biosciences Introduces the Cytek Orion™ Reagent Cocktail Preparation System, the First-of-its-Kind Automated Cocktail Preparation Instrument for Flow Cytometry
From Cytek Biosciences, Inc.
Via GlobeNewswire
Cytek's Full Spectrum Technology Stands Out In Cell Analysis Market, Bullish Analyst Says
Via Benzinga
Topics Supply Chain
Exposures Supply Chain
Cytek Biosciences to participate in the Piper Sandler 35th Annual Healthcare Conference
From Cytek Biosciences, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.